QUOTE AND NEWS
Benzinga  Oct 2  Comment 
Esperion Therapeutics (NASDAQ: ESPR) shares reached a new 52-week high of $27.905 after the company announced positive top-line Phase 2b results for ETC-1002. Sagent Pharmaceuticals (NASDAQ: SGNT) shares touched a new 52-week high of $32.12...
StreetInsider.com  Oct 1  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Sagent+Pharmaceuticals+%28SGNT%29+Acquires+Omega+Labs+in+%2485.3M+Deal/9877423.html for the full story.
Benzinga  Oct 1  Comment 
Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT) ("Sagent"), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that it has acquired Omega Laboratories Limited ("Omega"), a market leading specialty...
StreetInsider.com  Sep 26  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Sagent+Pharmaceuticals+%28SGNT%29+Launches+GLYDO/9863911.html for the full story.
Benzinga  Sep 23  Comment 
Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT) today announced the introduction of Oxaliplatin Injection, USP, an antineoplastic agent, now in two liquid presentations. According to IMS, for the 12 months ending July 2014, the US market for...
Benzinga  Sep 16  Comment 
Sino-Global Shipping America (NASDAQ: SINO) shares reached a new 52-week high of $3.93 after the company reported full year fiscal 2014 financial results. Sagent Pharmaceuticals (NASDAQ: SGNT) shares reached a new 52-week high of $30.67. Sagent...
SeekingAlpha  Jul 30  Comment 
Sagent Pharmaceuticals Inc (NASDAQ:SGNT) Q2 2014 Earnings Conference Call July 30, 2014 10:00 AM ET Executives Jim Polson - IR Jeff Yordon - Chairman and CEO Jonathon Singer - CFO Analysts Elliot Wilbur - Needham &...
Benzinga  Jul 25  Comment 
In a report published Friday, Bank of America analyst Sumant S. Kulkarni downgraded the rating on Sagent Pharmaceuticals (NASDAQ: SGNT) from Buy to Neutral, but raised the price target from $25.00 to $28.00. In the report, Bank of America noted,...
SeekingAlpha  May 6  Comment 
Sagent Pharmaceuticals Inc (SGNT) Q1 2014 Earnings Conference Call May 06, 2014 09:00 AM ET Executives Jim Polson – Senior Director, Strategic Communications, FTI Consulting Jeffrey M. Yordon – Chairman and Chief Executive...
Benzinga  Apr 21  Comment 
Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT) today announced the reintroduction of Adenosine Injection, USP, an antiarrhythmic agent, now in improved prefilled plastic syringes. According to IMS, for the 12 months ending February 2014, the US...




 
TOP CONTRIBUTORS

Sagent Pharmaceuticals (NASDAQ:SGNT) is a pharmaceutical company which sells injectable drugs. Sagent focuses on the generic injectable market in particular. In addition to selling and marking the drugs, Sagent also develops them and brings them through the Food and Drug Administration (FDA) approval process. With its first drug approved in 2007, Sagent has had an increasing number of drugs approved from then until is IPO.[1]

Sagnet focuses on developing generic drugs and therefore uses the Abbreviated New Drug Application (ANDA) process with the FDA. This process consists of the approval of an existing drug but simply in its generic form. Because they are the generic form of an existing drug, the approval process generally does not require the preclinical (animal) and clinical (human) trials. Instead, they must demonstrate similarity to the existing drug. By going through the ANDA process, the rate of approval is far greater and the intensity of research is lower for Sagent. However, the company may only apply for an ANDA when the patent on the non-generic version has expired.[2]

The company's initial public offering of stock on the NASDAQ occurred on April 19, 2011. The company offered 5.8M shares each for $16. This was at the high end of the initial price range of $14-$16. This brought the total deal size to $92M. The lead underwriters of the deal were Morgan Stanley (MS), Bank of America (BAC), and Jefferies Group (JEF).[3]

For the full year 2010, Sagent reported a total revenue of $74M. This was a substantial increase over the total revenue of $29M in 2009. However, the company reported a net loss for 2010 of $24.5M.[4]

References

  1. SGNT S-1/A 2011 PROSPECTUS SUMMARY "Overview" pg 1
  2. SGNT S-1/A 2011 PROSPECTUS SUMMARY "Our Competitive Strengths" pg 3-5
  3. Renaissance Capital - IPO Home "Sagent Pharmaceuticals prices upsized IPO at $16, high end of the range" 20 April 2011
  4. SGNT S-1/A 2011 PROSPECTUS SUMMARY "SUMMARY HISTORICAL CONSOLIDATED FINANCIAL DATA" pg 9
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki